APP and amyloidosis: Intraperitoneal injection of Leucettine L41, a compound preventing Dyrk1A proteolysis, inhibits STAT3a phosphorylation and decreases pro‐inflammatory cytokine expression levels (IL1‐β, TNF‐α, and IL‐12) and ameliorates amyloid plaque load, synaptic plasticity, and cognitive functions in aged APP/PS1 mice.54